Sponsor Dossier
Cipla
Sponsor Dossier for Cipla. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACIVIR
- Brand: ADALICIP
- Brand: AMBRICIP
- Brand: AMCAL
- Brand: Anterone
- Brand: APIXABAN CIPLA
- Brand: APIXAIR
- Brand: APOHEALTH
- Device (sponsor): Medicine chamber spacer
- Device (sponsor): Non-sterile scar management dressing, reusable
- Device (sponsor): Irrigation fluid, nasal
- Device (sponsor): Dressing, occlusive, silicone
About
Cipla is an Australian Private Company with ABN 46 132 155 063, registered in Victoria. The entity is active and registered for GST from 2008.
Portfolio
Cipla has 146 brands on the ARTG, of which 43 are indexable and 34 carry a Product Information document. 26 brands are PBS-listed, 3 have a PBAC outcome on record, and 6 have an AusPAR on record. Notable brands include ACIVIR, ADALICIP, AMBRICIP, AMCAL, Anterone, APIXABAN CIPLA, APIXAIR, APOHEALTH, ARX-LETROZOLE, ARX-LIRAGLUTIDE, ARX-METHOTREXATE, ARX-PIRFENIDONE.
Therapeutic focus
— Oncology: 34 brands — Cardiology: 21 brands — Respiratory: 20 brands — Infectious Disease: 12 brands — Endocrinology: 11 brands — Pain Management: 10 brands — Neurology: 9 brands — Immunology: 5 brands — Haematology: 4 brands — Gastroenterology: 4 brands — Renal: 3 brands — Rare Disease: 3 brands — Reproductive Health: 3 brands — Psychiatry: 2 brands — Dermatology: 2 brands — Musculoskeletal: 1 brand — Ophthalmology: 1 brand — Other: 1 brand
PBS footprint
26 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2024-03-01, across 3 brands with a PBAC outcome on record. The latest AusPAR is 2025-11-06, across 6 brands with an AusPAR on record.